LLY Down as Patients Regain Weight After Stopping Zepbound
Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
Why AstraZeneca Is Buying Icosovax For $1.1 Billion
Shares of Icosovax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vacci...
Why AstraZeneca Is Buying Icosavax For $1.1 Billion
Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vacci...
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.
AstraZeneca buys US vaccine company in $1.1bn deal
Britain's biggest drugmaker buying Seattle-based firm Icosavax, expanding vaccine and immune therapy business
Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover
Vaccines specialist Icosavax Inc (NASDAQ: ICVX) is set to surge 45% on Tuesday after agreeing to be taken over by Anglo-Swedish pharma group AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) for $838 million c...
This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal
AstraZeneca agreed to acquire respiratory vaccine developer Icosavax in a cash deal expected to close in the first quarter of next year.
AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion
AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disea...
AstraZeneca boosts RSV profile with $1.1bn Icosavax deal
AstraZeneca has bought US biopharmaceutical company, Icosavax Inc, for up to $1.1 billion. The Anglo-Swedish drugs maker said the deal will build on its expertise in respiratory syncytial virus (R...
AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln
Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.
AstraZeneca Is Feeling The Weight Of The Market In 2023
AstraZeneca's stock is trading below its April 2022 highs, but the company is executing well and making the right moves to return and stay in growth mode. The company has managed the decline in COV...
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
AstraZeneca is shelling out hundreds of millions to position itself to benefit from AI. Its competitors are following suit as the drug industry climbs onto the AI bandwagon.
Is Now the Right Time to Buy AstraZeneca Stock?
AstraZeneca's pipeline is huge, and it's buying more assets to develop too. It's also making a major play to enter the digital healthcare space.
Dividend Lovers Betting Big on 6 Goldman Sachs Top Conviction List Picks for 2024
This integrated giant is safer for investors looking to get positioned in the energy sector, has backed up some, and now yields a strong 4.17% dividend.
AstraZeneca, Diageo, Lloyds & other UK Banks: What London's brokers had to say today
Here's our daily round-up of what's been doing the rounds in the Square Mile.
Related Companies